Colorado PDAB will not pursue upper payment limit on Trikafta stateofreform.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stateofreform.com Daily Mail and Mail on Sunday newspapers.
Colorado board declares $200,000-a-year cystic fibrosis drug to be affordable fresnobee.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fresnobee.com Daily Mail and Mail on Sunday newspapers.
Colorado s new prescription drug review board decided in a first-in-the-nation vote that a medication costing more than $200,000 a year doesn t qualify as "unaffordable," based on the drug s benefits to patients and the availability of coupons to cover out-of-pocket costs.
Colorado’s new prescription drug review board decided that a medication costing more than $200,000 a year doesn’t qualify as “unaffordable,” based on the drug’s benefits to patients and the availability of coupons to cover out-of-pocket costs.
The Prescription Drug Affordability Board unanimously voted against declaring Trikafta, a drug to treat cystic fibrosis, unaffordable at a meeting Friday morning. If the board had determined it was unaffordable, it would have kicked off a process of setting a maximum price.